Antiretroviral Treatment-Associated Tuberculosis in a Prospective Cohort of HIV-Infected Patients Starting ART
Table 5
Cox proportional hazards for baseline predictors of ART-associated TB in HIV-infected patients commencing ART.
Baseline characteristics
Unadjusted HR (95% CI)
-value
Adjusted† HR (95% CI)
-value
Age (years)
40
1.42 (0.26–7.77)
.687
1.27 (0.21–7.80)
.798
30–39
0.43 (0.06–3.05)
.397
0.35 (0.05–2.64)
.308
<30
1
1
Sex
Females
1.19 (0.24–5.88)
.835
1.87 (0.34–10.21)
.468
Males
1
1
Tuberculin skin test (TST)
positive
0.78 (0.16–3.88)
.764
—
negative
1
—
C-reactive protein (mg/L)
≥5
8.23 (1.66–40.82)
.010
7.23 (1.36–38.33)
.020
<5
1
1
Haemoglobin (g/dL)
<12.5
6.66 (0.82–54.16)
.076
2.31 (0.23–23.43)
.477
≥12.5
1
1
CD4 cell counts (cells/μL)
<50
3.04 (0.72–12.74)
.129
2.22 (0.49–10.16)
.304
≥50
1
1
Body mass index (kg/m2)
<18.5
7.71 (1.92–30.89)
.004
5.85 (1.24–27.46)
.025
≥18.5
1
1
WHO clinical stage
3 and 4
4.68 (0.94–23.23)
.065
1.82 (0.33–10.18)
.495
1 and 2
1
1
†adjusted for age, sex, baseline C-reactive protein result, baseline haemoglobin, baseline CD4 counts, body mass index, and WHO clinical stage. Abbreviations: ART: antiretroviral therapy; TB: tuberculosis; HR: hazard ratio.
